It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.
The Janus kinase inhibitor (JAKi) class has been increasingly used in the management of axial spondyloarthritis (axSpA) over the past five years, offering effective oral alternatives to injectable biologics. But are all JAK inhibitors the same?
Dr. John Cush RheumNow
6 days 9 hours ago
The pain that inflammation does not explain in SpA and PsA
At EULAR 2026, the NEUPIA study (OP0317), a prospective observational investigation conducted at KU Leuven and University Hospitals Leuven, provides the most detailed longitudinal characterisation to date of these https://t.co/OYMf4KKBc1
Nelly ZIADE 🍀 Nellziade
6 days 20 hours ago
🏠 Take Home Messages from the early #axSpA session
🔺 Earlier diagnosis is possible and better
🔺 Early axSpA is not synonymous to mild
🔺 Longitudinally, early axSpA is heterogeneous
🔺 MRI has transformed the field
❗️Beware of pitfalls
#EULAR2026 @RheumNow https://t.co/IhGQSxssyd
The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented. Guidelines presented addressed several significant unmet need areas including PMR, GCA, Takayasu’s arteritis, Vaccinations in Rheumatic patients, Imaging in spondyloarthritis and classification criteria for the Anti-Synthetase Syndrome. Here are but a few of my favorites from a list of many quality sessions.
Jiha Lee JihaRheum
1 week ago
Patient-initiated telemedicine follow-up cut rheumatology visits by 25% in stable #SpA, but not equally for everyone. Reductions were greatest in men, axSpA, bDMARD users, and the oldest patients (64+, 34% fewer visits). Patient-centered care delivery @RheumNow #EULAR2026 POS1345
Dr. John Cush RheumNow
1 week ago
SELECT-Axis 2 trial and Withdrawal of Upadacitinib - Of 734 pts, 194 were in remission at wk104--> UPA w/d & 22% maintained drug-free remission for >48wks. Rest flared, median time to flare: 3.1 mos (89% regained LDA by wk24 w/ restart) #EULAR2026 #axSpA POS1350 https://t.co/7A7CAHxLxX
Dr. John Cush RheumNow
1 week ago
Risk of Parkinsons? RA patients have 28% lower Parkinson's risk vs general population (HR 0.72); axSpA had HIGHER risk (HR 1.29). Non-TNF biologics in RA reduced PD risk further (HR 0.74). No effect seen in PsA/axSpA. #EULAR2026 Abstr #POS1116 https://t.co/1vZoZGEu5Z
Nelly ZIADE 🍀 Nellziade
1 week ago
🏠 Take Home Messages from the early #axSpA session
🔺 Earlier diagnosis is possible and better
🔺 Early axSpA is not synonymous to mild
🔺 Longitudinally, early axSpA is heterogeneous
🔺 MRI has transformed the field
❗️Beware of pitfalls
#EULAR2026 @RheumNow
Nelly ZIADE 🍀 Nellziade
1 week ago
A high proportion of juvenile-onset SpA progress toward a r-axSpA phenotype
Results from the Spanish REGISPON-3
POS1352
#EULAR2026 @RheumNow https://t.co/XicguAdXJ1
Nelly ZIADE 🍀 Nellziade
1 week ago
How many patients with IBD have axSpA?
POS1338 #EULAR2026 @RheumNow
⬇️⬇️⬇️ https://t.co/29qkrCnDYz
Nelly ZIADE 🍀 Nellziade
1 week ago
Is the risk of uveitis comparable between infliximab sc and adalimumab in patients with r-axSpA and prior AAU?
Yes! POS 1347
Multicenter randomised open-label trial
N=56
#EULAR2026 @RheumNow https://t.co/kP7ropPkpC
Nelly ZIADE 🍀 Nellziade
1 week ago
What happens after withdrawal of upadacitinib in patients with axSpA who achieved remission?
Data from 194 patients from the SELECT-AXIS2 RCT:
▶️ Remission maintained in 1/4 at48 weeks
POS1350 #EULAR2026 @RheumNow https://t.co/Z7nDwMuQux
